As a former Chief Digital Officer for one of the world’s largest life sciences companies, lately I’ve been asked to speak about the biggest disruption to our industry in our lifetimes. From pharma leadership to investors and think tanks, to Ivy League universities, there’s a growing recognition that something fundamental has changed in how we discover and develop new medicines.
This is something that impacts the data of every regulatory submission, of every study, and every trial. It reaches across the entire discovery and development pipeline. And no, it’s not AI. Everyone is talking about AI, I’m talking about sex-based differences. Artificial intelligence changes how fast we analyze the data we have. Sex-based differences change whether we have the right data in the first place, in every study, dataset and regulatory submission.
Every cell in your body has a sex. It’s a simple fact with complex consequences. Many of the people I meet find it surprising that as an industry, we weren’t required to include women in studies in the US until 1993. Now that we are rethinking our default to male cells, male mice, and men, we are finally learning about cells that do not have a Y chromosome. As we are discovering in real time, these cells respond differently across organ systems.